Journal Mobile Options
Table of Contents
Vol. 51, No. 1, 2007
Issue release date: April 2007
Ann Nutr Metab 2007;51:88–95

Interleukin-6, C-Reactive Protein and Biochemical Parameters during Prolonged Intermittent Fasting

Aksungar F.B. · Topkaya A.E. · Akyildiz M.
Departments of aBiochemistry, bMicrobiology and cCardiovascular Surgery, Maltepe University, School of Medicine, Istanbul, Turkey

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: It is well known that nutritional habits, sleeping patterns and meal frequency have profound effects on maintaining human health. Ramadan is a religious month for Islam, during which Muslims do not eat and drink during the daylight hours. The duration of restricted food and beverage intake is approximately 12 h/day for 1 month, which makes Ramadan a model of prolonged intermittent fasting. Methods: In order to evaluate the effects of long-lasting modifications of food intake on inflammatory markers and biochemical parameters 40 healthy volunteers of normal weight [20 females aged between 20 and 38 years, 20 males aged between 23 and 39 years, body mass index (BMI) <25 kg/m2] who fasted during Ramadan and another 28 healthy age- and BMI-matched volunteers (14 males, 14 females) who did not fast participated in the study. Venous blood samples were taken 1 week before Ramadan, during the last week of Ramadan and 3 weeks after Ramadan. Serum interleukin-6 (IL-6), C-reactive protein (CRP), homocysteine, vitamin B12, folate, total cholesterol (TC), triglycerides, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels were measured. Results: No significant changes were observed in serum total cholesterol, triglycerides and LDL levels. TC/HDL ratio (HDL risk factor) was decreased during and after Ramadan in both genders in the fasting group while there were no changes in the nonfasting group. IL-6 (p < 0.001), CRP (p < 0.001) and homocysteine (p < 0.01) levels were significantly low during Ramadan in the fasting subjects of both genders when compared to basal values (1 week before Ramadan). Conclusion: Our results demonstrate that prolonged intermittent fasting in a model like Ramadan has some positive effects on the inflammatory status of the body and on the risk factors for cardiovascular diseases such as homocysteine, CRP and TC/HDL ratio.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bogdan A, Bouchareb B, Touitou Y: Ramadan fasting alters endocrine and neuroendocrine circadian patterns. Meal-time as a synchronizer in humans? Life Sci 2001;68:1607–1615.
  2. Aksungar FB, Eren A, Ure S, Teskin O, Ates G: Effects of intermittent fasting on serum lipid levels, coagulation status and plasma homocysteine levels. Ann Nutr Metab 2005;49:77–82.
  3. Bogdan A, Bouchareb B, Touitou Y: Response of circulating leptin to Ramadan daytime fasting: a circadian study. Br J Nutr 2005;93:515–518.
  4. Mohamed-Ali V, Goodrick S, Rawesh D, Katz DR, Miles JM, Yudkin JS, et al: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196–4200.
  5. Canavan B, Salem RO, Schurgin S, Koutkia P, Lipinska I, Laposata M, et al: Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab 2005;90:5779–5785.
  6. Hakkou F, Tazi A, Iraki L: Ramadan et santé. Proc 1st Int Congr Health Ramadan, Casablanca, 1994, pp 31–61.
  7. Selhub J: Homocysteine metabolism. Annu Rev Nutr 1999;19:217–246.
  8. Gerdes VE, Hovinga HA, Ten Cate H, Macgillavry MR, Leijte A, et al: Homocysteine and markers of coagulation and endothelial cell activation. J Thromb Haemost 2004;2:445–451.
  9. You T, Yang R, Lyles MF, Gong D, Nicklas BJ: Abdominal fat tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 2005;288:E741–E747.

    External Resources

  10. Konukoglu D, Hatemi H, Bayer H, Bagriacik N: Relationship between serum concentrations of interleukin-6 and tumor necrosis factor alpha in female Turkish subjects with normal and impaired glucose tolerance. Horm Metab Res 2006;38:34–37.
  11. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, et al: Impaired glucose tolerance is associated with increased serum concentrations of interleukin-6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologica 2002;45:805–812.
  12. Corpeleijin E, Saris WHM, Jansen E, Roekaerts P, Feskens E, Blaak E: Postprandial interleukin-6 release from skeletal muscle in men with impaired glucose tolerance can be reduced by weight loss. J Clin Endocrinol Metab 2005;90:5819–5824.
  13. Krumdieck CL, Prince CW: Mechanisms of homocysteine toxicity on connective tissues: implications for the morbidity of aging. J Nutr 2000;130:365S–368S.
  14. Jakubowski H: Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 2000;130:377S–381S.
  15. Dalal S, Parkins SM, Homer-Vanniasinkam S, Nicolaou A: Effect of homocysteine on cytokine production by human endothelial cells and monocytes. Ann Clin Biochem 2003;40:534–541.
  16. Berg M, Fraker DL, Alexander HR: Characterisation of differentiation factor/leukemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes. Cytokine 1994;6:425–432.
  17. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow Ro, Jablons D: Interleukin-6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin-6 in cancer cachexia. Cancer Res 1992;52:4113–4116.
  18. Akgun S, Ertel NH, Mosenthal A, Oser W: Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. J Lab Clin Med 1998;131:103–108.
  19. Haddy N, Sass C, Droesch S, Zaiou M, Siest G, Ponthieux A, Lambert D, Visvikis S: IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003;170:277–283.
  20. Onat A: Lipids, lipoproteins and apolipoproteins among Turks, and impact on coronary heart disease. Anadolu Kardiyol Derg 2004;4:236–245.

    External Resources

  21. Kinosian B, Glick H, Garland G: Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994;121:641–647.
  22. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–1847.
  23. Magliano DJ, Liew D, Ashton EL, Sundararajan V, McNeil JJ: Novel biomedical risk markers for cardiovascular disease. J Cardiovasc Risk 2003;10:41–55.
  24. Meier-Ewert H, Ridker P, Rifai N, Price N, Dinges DF, Mullington JM: Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001;47:426–430.
  25. Sothern RB, Roitman-Johnson B, Kanabrocki EL, Yager JG, Rodell MM, Weatherbee JA, et al: Circadian characteristics of circulating interleukin-6 in men. J Allergy Clin Immunol 1995;95:1029–1035.
  26. DeRijk R, Michelson D, Karp B, Petrides J, Galliven E, Deuster P, et al: Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) production in humans: high sensitivity of TNF-alpha and resistance to IL-6. J Clin Endocrinol Metab 1997;82:2182–2191.
  27. Yudkin JS, Stehouwer CH, Emeis JJ, et al: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972–978.
  28. Festa A, D’Agostino RJ, Howard G, et al: Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis study (IRAS). Circulation 2000;102:42–47.
  29. Ridker PM, Wilson PWF, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818–2825.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50